The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells

Journal of Biological Chemistry

Volumn 287, Issue 47, 2012, Pages 39812-39823

  Dai, Rongyang ^a,b,c   Li, Juanjuan ^a   Fu, Jing ^a   Chen, Yao ^a   Wang, Ruoyu ^a   Zhao, Xiaofang ^a   Luo, Tao ^a   Zhu, Junjie ^a   Ren, Yibin ^a   Cao, Jie ^a   Qian, Youwen ^a   Li, Ning ^a,b   Wang, Hongyang ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLANGIOCARCINOMA; DEPHOSPHORYLATIONS; HEPATOCYTE GROWTH FACTOR; HUMAN BILE; POTENTIAL MECHANISM; TYROSINE KINASE; TYROSINE PHOSPHATASE; UNDERLYING MECHANISM;

CELL PROLIFERATION; PHOSPHATASES;

AMINO ACIDS;

DENSITY ENHANCED PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; WESTERN BLOTTING;

BILE DUCT NEOPLASMS; CELL PROLIFERATION; CHOLANGIOCARCINOMA; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3;

EID: 84869238687     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.406520     Document Type: Article

References (53)

1. Figueras, J., Valls, C., and Jaurrieta, E. (2000) Biliary tract cancers. N. Engl. J. Med. 342, 663-664
2. Olnes, M. J., and Erlich, R. (2004) A review and update on cholangiocarcinoma. Oncology 66, 167-179 (Pubitemid 38813042)
3. 2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 280, 24053-24063
4. Patel, T. (2006) Cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 33-42
5. Wehbe, H., Henson, R., Meng, F., Mize-Berge, J., and Patel, T. (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 66, 10517-10524 (Pubitemid 44799774)
6. Farazi, P. A., Zeisberg, M., Glickman, J., Zhang, Y., Kalluri, R., and DePinho, R. A. (2006) Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66, 6622-6627 (Pubitemid 44085618)
7. 2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem. 281, 33982-33996
8. Terada, T., Nakanuma, Y., and Sirica, A. E. (1998) Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum. Pathol. 29, 175-180 (Pubitemid 28099514)
9. Leelawat, K., Leelawat, S., Tepaksorn, P., Rattanasinganchan, P., Leungchaweng, A., Tohtong, R., and Sobhon, P. (2006) Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J. Surg. Res. 136, 78-84 (Pubitemid 44634563)
10. Sirica, A. E. (2005) Cholangiocarcinoma. Molecular targeting strategies for chemoprevention and therapy. Hepatology 41, 5-15
11. Miyamoto, M., Ojima, H., Iwasaki, M., Shimizu, H., Kokubu, A., Hiraoka, N., Kosuge, T., Yoshikawa, D., Kono, T., Furukawa, H., and Shibata, T. (2011) Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br. J. Cancer 105, 131-138
12. Ferracini, R., Longati, P., Naldini, L., Vigna, E., and Comoglio, P. M. (1991) Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J. Biol. Chem. 266, 19558-19564 (Pubitemid 21908266)
13. Boccaccio, C., and Comoglio, P. M. (2006) Invasive growth.AMET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 6, 637-645 (Pubitemid 44140861)
14. You, H., Ding, W., Dang, H., Jiang, Y., and Rountree, C. B. (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54, 879-889
15. Graziani, A., Gramaglia, D., Cantley, L. C., and Comoglio, P. M. (1991) The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J. Biol. Chem. 266, 22087-22090 (Pubitemid 21908617)
16. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994)Amultifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (Pubitemid 24138623)
17. 2+ homeostasis converts Pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J. Biol. Chem. 287, 14586-14597
18. Ma, P. C., Maulik, G., Christensen, J., and Salgia, R. (2003) c-Met. Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22, 309-325 (Pubitemid 36791889)
19. Forte, G., Minieri, M., Cossa, P., Antenucci, D., Sala, M., Gnocchi, V., Fiaccavento, R., Carotenuto, F., De Vito, P., Baldini, P. M., Prat, M., and Di Nardo, P. (2006) Hepatocyte growth factor effects on mesenchymal stem cells. Proliferation, migration, and differentiation. Stem Cells 24, 23-33
20. Gay, B., Suarez, S., Weber, C., Rahuel, J., Fabbro, D., Furet, P., Caravatti, G., and Schoepfer, J. (1999) Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. J. Biol. Chem. 274, 23311-23315
21. Tajima, H., Matsumoto, K., and Nakamura, T. (1992) Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp. Cell Res. 202, 423-431
22. Zhang, Y. W., Su, Y., Volpert, O. V., and Vande Woude, G. F. (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U.S.A. 100, 12718-12723 (Pubitemid 37339965)
23. Wagner, E. F., and Nebreda, A. R. (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549
24. Maher, P. (1999) p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. J. Biol. Chem. 274, 17491-17498
25. Enslen, H., Raingeaud, J., and Davis, R. J. (1998) Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J. Biol. Chem. 273, 1741-1748 (Pubitemid 28133705)
26. Matsumoto, T., Yokote, K., Tamura, K., Takemoto, M., Ueno, H., Saito, Y., and Mori, S. (1999) Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J. Biol. Chem. 274, 13954-13960
27. Ono, K., and Han, J. (2000) The p38 signal transduction pathway. Activation and function. Cell. Signal. 12, 1-13 (Pubitemid 30017963)
28. Bulavin, D. V., and Fornace, A. J., Jr. (2004) p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95-118 (Pubitemid 39458114)
29. Hui, L., Bakiri, L., Stepniak, E., and Wagner, E. F. (2007) p38α. A suppressor of cell proliferation and tumorigenesis. Cell Cycle 6, 2429-2433 (Pubitemid 350058657)
30. Kogai, T., Liu, Y. Y., Mody, K., Shamsian, D. V., and Brent, G. A. (2012) Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells. J. Biol. Chem. 287, 3292-3300
31. Platanias, L. C. (2003) MAP kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679
32. v-src signaling in breast cancer cells. J. Biol. Chem. 274, 7341-7350
33. Neve, R. M., Holbro, T., and Hynes, N. E. (2002) Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21, 4567-4576 (Pubitemid 34785733)
34. Tan, F. L., Ooi, A., Huang, D., Wong, J. C., Qian, C. N., Chao, C., Ooi, L., Tan, Y. M., Chung, A., Cheow, P. C., Zhang, Z., Petillo, D., Yang, X. J., and Teh, B. T. (2010) p38δ/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int. J. Cancer 126, 2353-2361
35. Park, J., Tadlock, L., Gores, G. J., and Patel, T. (1999) Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30, 1128-1133 (Pubitemid 29510848)
36. Tadlock, L., and Patel, T. (2001) Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 33, 43-51 (Pubitemid 32016886)
37. Yamagiwa, Y., Marienfeld, C., Tadlock, L., and Patel, T. (2003) Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology 38, 158-166 (Pubitemid 36775807)
38. Recio, J. A., and Merlino, G. (2002) Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2, and cyclin D1. Oncogene 21, 1000-1008 (Pubitemid 34174512)
39. Trusolino, L., Bertotti, A., and Comoglio, P. M. (2010) MET signalling. Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848
40. Jeffers, M., Fiscella, M., Webb, C. P., Anver, M., Koochekpour, S., and Vande Woude, G. F. (1998) The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl. Acad. Sci. U.S.A. 95, 14417-14422 (Pubitemid 28549382)
41. Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., Vocke, C., Brown, J. A., Jenkins, R., Richard, S., Bergerheim, U., Gerrard, B., Dean, M., Linehan, W. M., and Zbar, B. (1999) Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 18, 2343-2350 (Pubitemid 29192711)
42. Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., and Vande Woude, G. F. (1997) Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. U.S.A. 94, 11445-11450 (Pubitemid 27451018)
43. Palka, H. L., Park, M., and Tonks, N. K. (2003) Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 278, 5728-5735 (Pubitemid 36800817)
44. Wang, Z., Wang, M., and Carr, B. I. (2010) Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. J. Cell. Physiol. 224, 559-565
45. Arora, D., Stopp, S., Böhmer, S. A., Schons, J., Godfrey, R., Masson, K., Razumovskaya, E., Rönnstrand, L., Tänzer, S., Bauer, R., Böhmer, F. D., and Müller, J. P. (2011) Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J. Biol. Chem. 286, 10918-10929
46. Kermorgant, S., Zicha, D., and Parker, P. J. (2003) Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J. Biol. Chem. 278, 28921-28929 (Pubitemid 36935802)
47. Jeffers, M., Taylor, G. A., Weidner, K. M., Omura, S., and Vande Woude, G. F. (1997) Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 17, 799-808 (Pubitemid 27044379)
48. Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., and Park, M. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (Pubitemid 34031802)
49. Carter, S., Urbé, S., and Clague, M. J. (2004) The met receptor degradation pathway. Requirement for Lys48-linked polyubiquitin independent of proteasome activity. J. Biol. Chem. 279, 52835-52839 (Pubitemid 40051783)
50. Li, N., Hill, K. S., and Elferink, L. A. (2008) Analysis of receptor tyrosine kinase internalization using flow cytometry. Methods Mol. Biol. 457, 305-317
51. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G. F. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (Pubitemid 37493640)
52. Corso, S., Comoglio, P. M., and Giordano, S. (2005) Cancer therapy. Can the challenge be MET? Trends Mol. Med. 11, 284-292 (Pubitemid 40804792)
53. Christensen, J. G., Burrows, J., and Salgia, R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225, 1-26 (Pubitemid 40732764)